NIZ985
Total Payments
$3.1M
Transactions
22
Doctors
1
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $970,117 | 6 | 0 |
| 2019 | $1.3M | 8 | 1 |
| 2018 | $617,427 | 5 | 0 |
| 2017 | $196,255 | 3 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.1M | 22 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE I IB STUDY OF SUBCUTANEOUS RECOMBINANT HUMAN NIZ985 ALONE AND IN COMBINATION WITH PDR001 IN ADULTS WITH METASTATIC CANCERS | Novartis Pharmaceuticals Corporation | $3.1M | 0 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $691.93 | 1 |
Top Doctors Receiving Payments for NIZ985
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Salt Lake City, UT | $3.1M | 20 |
| Thomas Waldmann | — | Silver Spring, MD | $691.93 | 2 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $3.1M
- Total Doctors 1
- Transactions 22
About NIZ985
NIZ985 is a drug associated with $3.1M in payments to 1 healthcare providers, recorded across 22 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $970,117 was paid across 6 transactions to 0 doctors.
The most common payment nature for NIZ985 is "Unspecified" ($3.1M, 100.0% of total).
NIZ985 is associated with 2 research studies, including "A PHASE I IB STUDY OF SUBCUTANEOUS RECOMBINANT HUMAN NIZ985 ALONE AND IN COMBINATION WITH PDR001 IN ADULTS WITH METASTATIC CANCERS" ($3.1M).